MSI-Highを有する去勢抵抗性前立腺癌に対するペムブロリズマブの使用経験

DOI HANDLE Web Site

書誌事項

タイトル別名
  • Experience of Pembrolizumab Administration in A Patient with Castration-Resistant Microsatellite Instability-High Prostate Cancer
  • MSI-High オ ユウスル キョセイ テイコウセイ ゼンリツセンガン ニ タイスル ペムブロリズマブ ノ シヨウ ケイケン

この論文をさがす

抄録

Castration-resistant prostate cancer and multiple lymph node and ventral bladder metastases in an 87 year-old man progressed despite various systemic therapies, including chemotherapy. Because his prostate surgical specimen displayed a microsatellite instability (MSI) -high status, pembrolizumab 200 mg/body treatment was started. After six courses of treatment, his prostate-specific antigen (PSA) level decreased by 83% versus that at treatment initiation (from 408.78 ng/ml to 69.54 ng/ml), and the para-aortic lymph node metastasis was reduced in size on imaging. After 13 courses, his PSA level (462.59 ng/ml) exceeded that at the start of treatment, and progressive disease was detected on imaging. Although case reports of pembrolizumab for MSI-high prostate cancer remain few because of its rarity, it is an important therapeutic option and further clinical research is required.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 70 (2), 51-54, 2024-02-29

    泌尿器科学術研究会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ